Skip to content
BioalmanacPeptide reference
Account
Menu

Comparison

Semaglutide vs liraglutide

Same receptor, same drug class, one generation apart. One is a weekly injection and produced about twice the weight reduction of the other, which is a daily one.

Both are GLP-1 receptor agonists and both hold approvals for weight management. Liraglutide came first; semaglutide is the later molecule, and the difference between them is mostly a difference in how long each stays in the body.

That one property drives everything you would notice. Liraglutide's half-life supports a daily injection, semaglutide's a weekly one. Seven a week against one. That is the biggest practical gap between two drugs doing the same job.

The efficacy gap is real and it is not subtle. Across their trial programmes semaglutide produced roughly double the mean weight reduction, and a later head-to-head found the same thing.

Semaglutide vs liraglutide compared row by row
AttributeSemaglutideLiraglutide
Receptor targetsGLP-1GLP-1
Evidence levelApprovedApproved
Dosing frequencyOnce weeklyOnce daily
Half-lifeAbout 7 daysAbout 13 hours
Injections per yearAbout 52About 365
Mean weight reduction in trialsAround 15% at the higher doseAround 8%
Most common reported side effectsNausea, vomiting, constipationNausea, vomiting, diarrhoea

Things worth knowing

  • The side effects come from the same family for both, and both are dose-dependent. Neither turns out to be the gentler option once you titrate them to a comparable effect.
  • Liraglutide's shorter half-life cuts both ways. A bad reaction clears faster. A missed dose costs more.
  • Both are approved drugs, and the approved versions are prescribed and supervised. Neither trial programme tested anything that arrives in a vial labelled for research.

Full profile

Semaglutide

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.

Full profile

Liraglutide

The first GLP-1 analogue approved for weight loss. A daily injection, superseded by weekly semaglutide but still the best-documented compound in the class.

Related

Another comparisonRetatrutide vs semaglutideOne receptor against three, and a finished approval against a trial programme still running. The largest reported effect in the class, set beside the most established one.Another comparisonSemaglutide vs cagrilintideTwo different satiety pathways, usually discussed as a pair rather than a choice. One is an approved drug on its own; the other is mostly studied alongside it.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.